Summary

The US generic drug market size reached USD 93.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 126.0 Billion by 2033, exhibiting a growth rate (CAGR) of 3.4% during 2025-2033. The increasing prevalence of chronic diseases, the rising geriatric population, the growing healthcare expenditure, a large number of patent-expired branded drugs, and the escalating demand for generic medicines are some of the factors propelling the market.

A generic drug is a pharmaceutical product that is bioequivalent to a brand-name drug in terms of dosage, strength, safety, efficacy, route of administration, and intended use. It is produced and marketed after the patent protection of the original brand-name drug expires. These medications contain the same active ingredients as their brand-name counterparts and undergo rigorous testing by regulatory authorities to ensure their quality, safety, and effectiveness. Generic drugs offer several advantages, including lower cost, increased accessibility, and greater affordability, making healthcare more affordable and accessible to a wider population. They play a crucial role in providing cost-effective alternatives to brand-name drugs, promoting competition in the pharmaceutical market, and enhancing the overall efficiency of healthcare systems in the United States.

The market in the United States is majorly driven by the easy availability and affordability of the product. In line with this, the increasing number of expired patents is significantly contributing to the market. Apart from this, with the rising cost of healthcare, including prescription medications, payers and healthcare providers seek to promote the use of generic drugs to contain expenses, thus catalyzing the market. Moreover, numerous government initiatives encourage the use of generic drugs by providing incentives and lower reimbursement rates for generic prescriptions, thereby creating a positive outlook for the market. Besides, the aging population in the United States requires a larger volume of medications. Additionally, the expiration of patents for several blockbuster drugs creates growth opportunities for generic manufacturers.

US Generic Drug Market Trends/Drivers:
Growing demand for chronic disease management

The growing demand for chronic disease management is favorably impacting the market. Chronic diseases, such as diabetes, cardiovascular conditions, and respiratory disorders, are prevalent and require long-term medication use. As the population ages and the prevalence of chronic diseases increases, the need for cost-effective medication options becomes crucial. Furthermore, generic drugs offer an affordable alternative for managing chronic diseases. They contain the same active ingredients as their brand-name counterparts, ensuring similar therapeutic effects at a fraction of the cost. This makes them highly attractive to patients, healthcare providers, and payers. Moreover, healthcare providers often prioritize using generic drugs for chronic disease management due to their proven safety and efficacy. They may prescribe generics as a first-line treatment option or encourage patients to switch from brand-name medications to their generic equivalents to improve adherence and reduce costs. In addition, the payers, including insurance companies and government programs, recognize the cost-saving potential of generic drugs in chronic disease management. They may offer preferential coverage or lower co-pays for generic prescriptions, making them more accessible and affordable for patients. Additionally, formulary management programs may include generics as preferred options, further driving their utilization.

Increasing drug shortage across the region

The increasing drug shortage is strengthening the market across the region. Shortages of brand-name drugs can occur due to a variety of factors, including manufacturing issues, regulatory challenges, supply chain disruptions, and increased demand. These shortages can lead to increased utilization of generic alternatives. During a drug shortage, healthcare providers and pharmacies may face challenges maintaining a consistent supply of brand-name medications. As a result, they turn to generic drugs as a substitute to ensure continuity of patient care. Generic drugs offer a viable solution during these shortages as they are often readily available, produced by multiple manufacturers, and competitively priced. Furthermore, healthcare providers may proactively prescribe generic drugs as alternatives to mitigate the impact of drug shortages on patient treatment plans. In some cases, healthcare systems and hospitals may implement protocols to promote the use of generic drugs during shortages to optimize resource allocation and minimize disruptions in patient care. Moreover, the reliance on generic drugs during drug shortages addresses immediate supply challenges and contributes to the growth of the generic drug market in the long term. This creates an opportunity for healthcare providers, patients, and payers to recognize the value and reliability of generic medications, potentially leading to increased utilization and market growth for generic drugs beyond the period of shortage.

Presence of patent cliffs

Patent cliffs refer to the expiration of patents for blockbuster brand-name drugs, opening the market for generic competitors. When a patent expires, generic manufacturers can legally produce and distribute their drug versions, often at significantly lower prices. Furthermore, patent cliffs are offering lucrative opportunities for generic drug manufacturers to enter the market and offer more affordable alternatives to brand-name drugs. As patents expire, competition increases, leading to the market growth for generic drugs. This increased competition promotes price transparency and drives down the cost of medications, benefiting patients and healthcare systems. Moreover, pharmaceutical companies and healthcare providers closely monitor patent expirations to identify cost savings opportunities and promote the usage of generics. They may proactively switch patients to generic alternatives to take advantage of the cost savings. Additionally, the presence of patent cliffs in the pharmaceutical industry expands access to more affordable medications and fosters market growth for generic drugs by creating a competitive landscape and encouraging innovation among generic manufacturers.

US Generic Drug Industry Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the US generic drug market report, along with forecasts at the regional and country levels from 2025-2033. Our report has categorized the market based on segment, therapy area, drug delivery, and distribution channel.

Breakup by Segment:

? Unbranded
? Branded

Unbranded dominates the market

The report has provided a detailed breakup and analysis of the market based on segment. This includes unbranded and branded generics. According to the report, unbranded generics represented the largest segment.

Unbranded generics, or non-proprietary or off-patent generics, refer to generic drugs not associated with any specific brand name. These medications are typically identified by their active pharmaceutical ingredient (API) and are often marketed under their generic names. They are experiencing high acceptance and utilization among healthcare providers and patients in Europe. These medications offer cost-effective alternatives to brand-name drugs, as they are generally priced lower due to competition from multiple manufacturers.

The affordability and accessibility of unbranded generics make them a preferred choice for healthcare providers, payers, and patients looking for cost savings and value-based healthcare solutions. The market share of unbranded generics reflects a competitive generic drug market in the US. This competition fosters price transparency, encourages innovation among generic manufacturers, and drives down healthcare costs. The presence of a wide range of unbranded generics in the market promotes choice, affordability, and accessibility of medications across the US.

Breakup by Therapy Area:

? CNS
? Cardiovascular
? Dermatology
? Genitourinary/Hormonal
? Respiratory
? Rheumatology
? Diabetes
? Oncology
? Others

A detailed breakup and analysis of the market based on the therapy area have also been provided in the report. This includes CNS, cardiovascular, dermatology, genitourinary/hormonal, respiratory, rheumatology, diabetes, and oncology.

CNS therapy encompasses conditions targeted at depression, anxiety, and neurological disorders. The availability of generic drugs allows for cost-effective treatment options for these disorders. The affordability of generic CNS medications increases patient access to essential treatments and contributes to the growth of the generic drug market.

Furthermore, the cardiovascular segment covers medications for heart-related conditions like hypertension and heart failure. Generic drugs provide cost savings and promote adherence to treatment plans. The availability of generic cardiovascular medications allows patients and healthcare providers to manage these chronic conditions more affordably, catalyzing the market.

Moreover, dermatology includes treatments for skin conditions like acne, eczema, and psoriasis, the availability of generic medications offers cost-effective solutions. These generic alternatives make dermatological treatments more accessible, augmenting market growth by expanding patient access and reducing healthcare costs. Besides, these medications enable targeted approaches to specific medical needs. It ensures that a wide range of diseases and conditions can be effectively managed with affordable and high-quality generic medications, driving the overall market growth and improving healthcare outcomes.

Breakup by Drug Delivery:

? Oral
? Injectables
? Dermal/Topical
? Inhalers

Oral holds the largest share of the market

A detailed breakup and analysis of the market based on drug delivery have also been provided in the report. This includes oral, injectables, dermal/topical, and inhalers. According to the report, oral accounted for the largest market share.

Oral drugs are widely favored by patients and healthcare providers due to their convenience and ease of administration, often requiring minimal or no medical assistance. The popularity of oral drugs stems from their ability to be self-administered, allowing patients to take their medication in the comfort of their homes without needing injections or medical procedures. This convenience factor improves patient adherence to treatment plans, ultimately improving health outcomes.

Furthermore, the availability of generic oral drugs provides cost-effective alternatives to brand-name medications in this segment. Generic oral drugs undergo rigorous testing to ensure bioequivalence with their brand-name counterparts, offering the same therapeutic benefits at a lower cost. This affordability and accessibility of generic oral drugs contribute to their market growth, as they meet the demand for convenient and self-administered medications while providing significant cost savings for patients and healthcare systems.

Breakup by Distribution Channel:

? Hospital Pharmacies
? Retail Pharmacies

Hospital Pharmacies hold the largest share of the market

A detailed breakup and analysis of the market based on the distribution channel have also been provided in the report. This includes hospital pharmacies and retail pharmacies. According to the report, hospital pharmacies accounted for the largest market share.

Hospital pharmacies are critical in supplying medications to patients within the healthcare system, including inpatient settings, outpatient clinics, and emergency departments. The prevalence of hospital pharmacies in the distribution of generic drugs is attributed to several factors. Hospitals require a significant volume of medications to meet the needs of their patient population. Generic drugs, known for their cost-effectiveness, are favored options for hospitals to manage medication costs while ensuring quality patient care.

Furthermore, hospital formularies often prioritize using generic drugs due to their proven efficacy and cost savings. This encourages healthcare providers within hospital settings to prescribe and administer generic drugs whenever possible. Moreover, the centralized nature of hospital pharmacies allows for efficient procurement, storage, and distribution of generic medications. Hospitals can leverage their purchasing power to negotiate favorable pricing agreements with generic drug manufacturers. The dominance of hospital pharmacies in distributing generic drugs drives market growth by promoting the use of cost-effective alternatives within the healthcare system. The high volume of medication sales through hospital pharmacies demonstrates these institutions' significant role in the accessibility and utilization of generic drugs in the United States.

Competitive Landscape:
The top generic drug companies in the United States actively contribute to the market expansion with their extensive resources, research capabilities, and industry expertise. These companies invest heavily in research and development to bring a wide range of generic drugs. They focus on developing cost-effective alternatives to brand-name medications across various therapy areas, addressing the needs of patients and healthcare providers for affordable treatment options. Furthermore, these companies maintain strong manufacturing capabilities and efficient supply chains, ensuring a steady and reliable supply of generic medications. This enables healthcare providers to confidently prescribe and dispense generic drugs, promoting their utilization and market growth. Besides, these companies engage in strategic partnerships, collaborations, and licensing agreements to enhance their product portfolios and expand market reach. By partnering with other industry leaders, they access a broader range of products, expertise, and distribution channels, allowing for increased market penetration and growth. Moreover, top generic drug companies engage in comprehensive marketing and promotional efforts to raise awareness among healthcare providers and patients about the benefits of generic drugs. They actively participate in educational initiatives, formulary discussions, and healthcare conferences, aiming to promote the value and cost-effectiveness of generic medications.

The report has provided a comprehensive analysis of the competitive landscape in the US generic drug market. Detailed profiles of all major companies have also been provided.

? Teva
? Mylan
? Actavis (Teva)
? Sandoz (Novartis)
? Sun Pharma
? Par Pharmaceuticals (Endo Pharmaceuticals)
? Lupin Pharmaceuticals
? Dr Reddy’s
? Hospira (Pfizer)

Recent Developments:
In 2020, Teva announced a collaboration with Amgen, a biotechnology company, to launch two biosimilar drugs in the United States. The collaboration aimed to bring more affordable and accessible treatment options to patients.
In 2020, Mylan, a global pharmaceutical company, finalized its merger with Pfizer's Upjohn division to form Viatris. This merger was a significant development in the generic drugs industry, as it created one of the largest global players in the generic and biosimilar markets.
In 2020, Actavis announced a collaboration with Celltrion Healthcare, a global biopharmaceutical company, to commercialize two biosimilar products in the United States. The collaboration aimed to bring cost-effective alternatives to biologic drugs for patients in the US market.

Key Questions Answered in This Report
1.What was the size of the US generic drug in 2024?
2.What is the expected growth rate of the US generic drug during 2025-2033?
3.What are the key factors driving the US generic drug market?
4.What has been the impact of COVID-19 on the US generic drug market?
5.What is the breakup of the US generic drug market based on the segment?
6.What is the breakup of the US generic drug market based on the therapy area?
7.What is the breakup of the US generic drug market based on the drug delivery?
8.What is the breakup of the US generic drug market based on the distribution channel?
9.Who are the key companies/players in the US generic drug market?

ページTOPに戻る

Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 US Generic Drug Market - Introduction
4.1 What are Generic Drugs
4.2 Unbranded and Branded Generics
4.3 Authorized Generics
4.4 Commoditized and Specialty Generics
5 Why is the US Generic Drug Market So Lucrative
5.1 Patent Expiry of Blockbuster Drugs
5.2 Significant Price Differential between Generics and Innovator Drugs
5.3 Savings for the Government and Third-Party Payers
5.4 Incentives for Dispensing and Prescribing Generic Drugs
5.5 Reimbursement and Lower Co-payments
5.6 Biosimilars
6 Global Generic Drug Market
6.1 Market Performance
6.1.1 Volume Trends
6.1.2 Value Trends
6.2 Market Breakup by Country
6.3 Market Forecast
6.4 Most Prescribed Generic and Branded Drugs
7 US Generic Drug Market
7.1 US Pharmaceutical Market Performance
7.1.1 Volume Trends
7.1.2 Value Trends
7.1.3 Market Breakup by Type
7.1.4 Market Forecast
7.2 US Generic Drug Market Performance
7.2.1 Volume Trends
7.2.2 Value Trends
7.2.3 Impact of COVID-19
7.2.4 Market Breakup by Segment
7.2.5 Market Breakup by Therapy Area
7.2.6 Market Breakup by Drug Delivery
7.2.7 Market Breakup by Distribution Channel
7.2.8 Market Forecast
8 Market Breakup by Segment
8.1 Unbranded Generics
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Branded Generics
8.2.1 Market Trends
8.2.2 Market Forecast
9 Market Breakup by Therapy Area
9.1 CNS
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Cardiovascular
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Dermatology
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Genitourinary/Hormonal
9.4.1 Market Trends
9.4.2 Market Forecast
9.5 Respiratory
9.5.1 Market Trends
9.5.2 Market Forecast
9.6 Rheumatology
9.6.1 Market Trends
9.6.2 Market Forecast
9.7 Diabetes
9.7.1 Market Trends
9.7.2 Market Forecast
9.8 Oncology
9.8.1 Market Trends
9.8.2 Market Forecast
9.9 Others
9.9.1 Market Trends
9.9.2 Market Forecast
10 Market Breakup by Drug Delivery
10.1 Oral
10.1.1 Market Trends
10.1.2 Market Forecast
10.2 Injectables
10.2.1 Market Trends
10.2.2 Market Forecast
10.3 Dermal/Topical
10.3.1 Market Trends
10.3.2 Market Forecast
10.4 Inhalers
10.4.1 Market Trends
10.4.2 Market Forecast
11 Market Breakup by Distribution Channel
11.1 Retail Pharmacies
11.1.1 Market Trends
11.1.2 Market Forecast
11.2 Hospital Pharmacies
11.2.1 Market Trends
11.2.2 Market Forecast
12 US Generic Drug Market - SWOT Analysis
12.1 Overview
12.2 Strengths
12.3 Weaknesses
12.4 Opportunities
12.5 Threats
13 US Generic Drug Market - Value Chain Analysis
13.1 Research and Development
13.2 Raw Material Procurement
13.3 Manufacturing
13.4 Marketing
13.5 Distribution
13.6 End-Consumer
14 Pricing Mechanism and Profit Margins at Various Levels of the Supply Chain
15 Porter’s Five Forces Analysis
15.1 Overview
15.2 Bargaining Power of Buyers
15.3 Bargaining Power of Suppliers
15.4 Degree of Rivalry
15.5 Threat of New Entrants
15.6 Threat of Substitutes
16 US Generic Drug Market- Competitive Landscape
16.1 US Generic Drug Market - Competitive Structure
16.2 US Generic Drug Market - Breakup of Key Players
16.3 US Generic Drug Market - Most Prescribed Generic Drugs
16.4 US Generic Drug Market - Market Breakup by Distribution
16.5 US Generic Drug Market - Pricing Dynamics
17 Regulations in the US Generic Drug Industry
17.1 Overview of Pharmaceutical Regulations
17.2 Drug Applications
17.3 Patents and Market Exclusivity
17.4 Regulatory Requirements for Generic Drugs
17.5 The Hatch-Waxman Act
17.6 Certifications
17.7 Other Important Considerations
18 US Generic Drug Market: Key Success Factors
19 US Generic Drug Market: Road Blocks
20 Requirements for Setting Up a Generic Drug Manufacturing Plant
20.1 Manufacturing Process
20.2 Raw Material Requirements
20.3 Raw Materials Pictures
20.4 Land and Construction Requirements
20.5 Machinery and Infrastructure Requirements
20.6 Machinery Pictures
20.7 Plant Layout
20.8 Packaging Requirements
20.9 Utility Requirements
20.10 Manpower Requirements
21 US Generic Drug Market - Key Company Profiles
21.1 Teva
21.2 Mylan
21.3 Actavis (Teva)
21.4 Sandoz (Novartis)
21.5 Sun Pharma
21.6 Par Pharmaceuticals (Endo Pharmaceuticals)
21.7 Lupin Pharmaceuticals
21.8 Dr Reddy’s
21.9 Hospira (Pfizer)

ページTOPに戻る

List of Tables/Graphs

List of Figures

Figure 1: Structure of the Pharmaceutical Industry
Figure 2: Classification of Generic Drugs
Figure 3: US: Patent Expiry Exposure (in Billion USD), 2019-2024
Figure 4: US: Savings from Generic Drugs (in Billion USD), 2019-2024
Figure 5: Global: Generic Drug Market: Sales Value (in Billion USD), 2019-2024
Figure 6: Global: Generic Drug Market: Sales Volume (in Billion Standards Units), 2019-2024
Figure 7: Global: Generic Drug Market: Sales Value Breakup by Country (in %), 2024
Figure 8: Global: Generic Drug Market: Sales Volume Breakup by Country (in %), 2024
Figure 9: Global: Generic Drug Market Forecast: Sales Value (in Billion USD), 2025-2033
Figure 10: Global: Generic Drug Market Forecast: Sales Volume (in Billion Standards Units), 2025-2033
Figure 11: US: Pharmaceutical Market: Sales Volume (in Million Prescriptions), 2019-2024
Figure 12: US: Pharmaceutical Market: Sales Value (in Billion USD), 2019-2024
Figure 13: US: Pharmaceutical Market: Sales Volume Breakup of Branded and Generic Drugs (in %), 2019 & 2024
Figure 14: US: Pharmaceutical Market: Sales Value Breakup of Branded and Generic Drugs (in %), 2019 & 2024
Figure 15: US: Pharmaceutical Market Forecast: Sales Volume (in Million Prescriptions), 2025-2033
Figure 16: US: Pharmaceutical Market Forecast: Sales Value (in Billion USD), 2025-2033
Figure 17: US: Generic Drug Market: Sales Volume (in Million Prescriptions), 2019-2024
Figure 18: US: Generic Drug Market: Sales Value (in Billion USD), 2019-2024
Figure 19: US: Generic Drug Market: Breakup by Segment (in %), 2024
Figure 20: US: Generic Drug Market: Breakup by Therapy Area (in %), 2024
Figure 21: US: Generic Drug Market: Breakup by Drug Delivery (in %), 2024
Figure 22: US: Generic Drug Market: Breakup by Distribution Channel (in %), 2024
Figure 23: US: Generic Drug Market Forecast: Sales Volume (in Million Prescriptions), 2025-2033
Figure 24: US: Generic Drug Market Forecast: Sales Value (in Billion USD), 2025-2033
Figure 25: Generic Drug Market: Price Structure
Figure 26: US: Generic Drug Industry: SWOT Analysis
Figure 27: US: Generic Drug Industry: Value Chain Analysis
Figure 28: US: Generic Drug Industry: Pricing Mechanism and Profit Margins at the Various Levels of the Supply Chain
Figure 29: US: Generic Drug Industry: Porter's Five Forces Analysis
Figure 30: US: Generic Drug Market: Unbranded Generics (in Million Prescriptions), 2019 & 2024
Figure 31: US: Generic Drug Market Forecast: Unbranded Generics (in Million Prescriptions), 2025-2033
Figure 32: US: Generic Drug Market: Branded Generics (in Million Prescriptions), 2019 & 2024
Figure 33: US: Generic Drug Market Forecast: Branded Generics (in Million Prescriptions), 2025-2033
Figure 34: US: Generic Drug Market: CNS (in Million USD), 2019 & 2024
Figure 35: US: Generic Drug Market Forecast: CNS (in Million USD), 2025-2033
Figure 36: US: Generic Drug Market: Cardiovascular (in Million USD), 2019 & 2024
Figure 37: US: Generic Drug Market Forecast: Cardiovascular (in Million USD), 2025-2033
Figure 38: US: Generic Drug Market: Dermatology (in Million USD), 2019 & 2024
Figure 39: US: Generic Drug Market Forecast: Dermatology (in Million USD), 2025-2033
Figure 40: US: Generic Drug Market: Genitourinary/Hormonal (in Million USD), 2019 & 2024
Figure 41: US: Generic Drug Market Forecast: Genitourinary/Hormonal (in Million USD), 2025-2033
Figure 42: US: Generic Drug Market: Respiratory (in Million USD), 2019 & 2024
Figure 43: US: Generic Drug Market Forecast: Respiratory (in Million USD), 2025-2033
Figure 44: US: Generic Drug Market: Rheumatology (in Million USD), 2019 & 2024
Figure 45: US: Generic Drug Market Forecast: Rheumatology (in Million USD), 2025-2033
Figure 46: US: Generic Drug Market: Diabetes (in Million USD), 2019 & 2024
Figure 47: US: Generic Drug Market Forecast: Diabetes (in Million USD), 2025-2033
Figure 48: US: Generic Drug Market: Oncology (in Million USD), 2019 & 2024
Figure 49: US: Generic Drug Market Forecast: Oncology (in Million USD), 2025-2033
Figure 50: US: Generic Drug Market: Others (in Million USD), 2019 & 2024
Figure 51: US: Generic Drug Market Forecast: Others (in Million USD), 2025-2033
Figure 52: US: Generic Drug Market: Oral (in Million USD), 2019 & 2024
Figure 53: US: Generic Drug Market Forecast: Oral (in Million USD), 2025-2033
Figure 54: US: Generic Drug Market: Injectables (in Million USD), 2019 & 2024
Figure 55: US: Generic Drug Market Forecast: Injectables (in Million USD), 2025-2033
Figure 56: US: Generic Drug Market: Dermal/Topical (in Million USD), 2019 & 2024
Figure 57: US: Generic Drug Market Forecast: Dermal/Topical (in Million USD), 2025-2033
Figure 58: US: Generic Drug Market: Inhalers (in Million USD), 2019 & 2024
Figure 59: US: Generic Drug Market Forecast: Inhalers (in Million USD), 2025-2033
Figure 60: US: Generic Drug Market: Retail Pharmacies (in Million USD), 2019 & 2024
Figure 61: US: Generic Drug Market Forecast: Retail Pharmacies (in Million USD), 2025-2033
Figure 62: US: Generic Drug Market: Hospital Pharmacies (in Million USD), 2019 & 2024
Figure 63: US: Generic Drug Market Forecast: Hospital Pharmacies (in Million USD), 2025-2033
Figure 64: US: Generic Drug Market: Sales Breakup of Top Players (in %)
Figure 65: US: Generic Drug Market: Volume Share of Top Players (in %)
Figure 66: US: Generic Drug Market: Volume Share by Distribution (in %)
Figure 67: US: Generic Drug Prices as a Percentage of Branded Drug Prices ? Based on Number of Competitors
Figure 68: US: Generic Drug Market: Detailed Process Flow
Figure 69: US: Generic Drug Market: Raw Material Requirements
Figure 70: US: Generic Drug Market: Plant Layout
Figure 71: US: Generic Drug Market: Packaging Requirements

List of Tables

Table 1: US: Sales and Patent Expiry of Major Drugs Expected to Lose Patent Protection (in Billion USD)
Table 2: US: Expenses of Generic and Branded Drug Manufacturers (in %)
Table 3: Global: Generic Drug Market: Volume Performance of Top Generic Drugs (in Million Prescriptions)
Table 4: Global: Branded Drug Market: Volume Performance of Top Branded Drugs (in Million Prescriptions)
Table 5: US: Generic Drug Market: Sales Performance of Top Players (in Billion USD), 2024
Table 6: US: Generic Drug Market: Volume Performance of Top Players (in Billion Units), 2024
Table 7: US: Generics Market: Volume Performance of Top Generic Drugs (in Million Prescriptions), 2024
Table 8: US: Overview of Pharmaceutical Regulations
Table 9: US: Generic Drug Market: Land and Construction Requirements
Table 10: US: Generic Drug Market: Machinery and Infrastructure Requirements
Table 11: US: Generic Drug Market: Utility Requirements
Table 12: US: Generic Drug Market: Manpower Requirements